INmune Bio, Inc. – NASDAQ:INMB

Add to watchlist

$2.41

-2.24

-48.17%

Market closed

Open in about 9 hours

-49.67%

month

-49.67%

quarter

-58.56%

year

Market Cap	98.88M
Enterprise value	101.79M

P/E	-5
EV/Sales	272.17
EV/EBITDA	-3.72
Price/Sales	370.68
Price/Book	2.30
PEG ratio	-0.31
EPS	-1.92

Revenue	131K
EBITDA	-34.33M
Income	-34.49M
Revenue Q/Q	-63.15%
Revenue Y/Y	-47.38%

Profit margin	-7299.2%
Oper. margin	-6938.77%
Gross margin	0%
EBIT margin	-6938.77%
EBITDA margin	-26209.92%

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

INmune Bio, Inc. (NASDAQ:INMB): Profit margin
Jun 2023	46K	-6.50M	-14132.61%
Sep 2023	43K	-8.56M	-19913.95%
Dec 2023	28K	-8.40M	-30028.57%
Mar 2024	14K	-11.02M	-78750%

INmune Bio Financials Estimate

Q Y

INmune Bio, Inc. (NASDAQ:INMB): Analyst Estimates
2025	29K	-48.46M	-167127.59%
2026	29.5K	-49.05M	-166274.58%
2027	82.70M	24.45M	29.57%
2028	146.16M	73.09M	50.01%

Analysts Price target
Financials & Ratios estimates

INmune Bio, Inc. (NASDAQ:INMB): Debt to assets
Jun 2023	69720000	19.06M	27.35%
Sep 2023	62698000	17.96M	28.65%
Dec 2023	57001000	18.86M	33.09%
Mar 2024	46833000	17.81M	38.03%

INmune Bio, Inc. (NASDAQ:INMB): Cash Flow
Jun 2023	-3.17M	0	0
Sep 2023	-4.26M	-2.55M	-1.72M
Dec 2023	-3.40M	2.55M	-2.5M
Mar 2024	-7.47M	0	-2.5M

INmune Bio alternative data

Social Media

🎓 Academy: How impactful can social media data be in investment decisions

INmune Bio, Inc. (NASDAQ:INMB): Employee count
Aug 2023	10
Sep 2023	10
Oct 2023	10
Nov 2023	10
Dec 2023	10
Jan 2024	10
Feb 2024	10
Mar 2024	10
Apr 2024	10
May 2024	11
Jun 2024	11
Jul 2024	11

INmune Bio
Hedge Funds Holdings Q1 2023

3.82% -5.34%

of INMB is owned by hedge funds

18 -13

hedge funds hold INMB stock

685.51K -959.49K

shares is hold by hedge funds

INMB hedge funds holdings changes

INmune Bio, Inc. (NASDAQ:INMB): Insider trades (number of shares)
Period	Buy	Sel
Nov 2023	7000	0
Apr 2024	160164	0
Jun 2024	5000	0
Sep 2024	56140	0

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Purchase	30 Sep 2024	MOSS DAVID J 10 percent owner, officer: Chief Financial Of.. 10 percent owner, officer: Chie..	Common Stock	10,000	$5.29	$52,870
Purchase	12 Sep 2024	TESI RAYMOND JOSEPH director, 10 perc..	Common Stock	15,380	$6.38	$98,048
Purchase	12 Sep 2024	TESI RAYMOND JOSEPH director, 10 perc..	Common Stock Warrants (right to buy)	15,380	$6.4	$98,432
Purchase	12 Sep 2024	MOSS DAVID J 10 percent owner, officer: Chief Financial Of.. 10 percent owner, officer: Chie..	Common Stock	7,690	$6.38	$49,024
Purchase	12 Sep 2024	MOSS DAVID J 10 percent owner, officer: Chief Financial Of.. 10 percent owner, officer: Chie..	Common Stock Warrants (right to buy)	7,690	$6.4	$49,216
Purchase	25 Jun 2024	JUDA SCOTT director director	Common Stock	5,000	$7.27	$36,350
Purchase	19 Apr 2024	MOSS DAVID J 10 percent owner, officer: CFO, Treasurer & S.. 10 percent owner, officer: CFO,..	Common Stock	18,028	$8.32	$149,993
Purchase	19 Apr 2024	MOSS DAVID J 10 percent owner, officer: CFO, Treasurer & S.. 10 percent owner, officer: CFO,..	Common Stock Warrants (right to buy)	18,028	$9.15	$164,992
Purchase	19 Apr 2024	TESI RAYMOND JOSEPH director, 10 perc..	Common Stock	18,028	$8.32	$149,993
Purchase	19 Apr 2024	TESI RAYMOND JOSEPH director, 10 perc..	Common Stock Warrants (right to buy)	18,028	$9.15	$164,992

Status	Patent	Filling date	Issue date
Application	Application TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS Filling date: 13 May 2020 Issue date: 4 Aug 2022	13 May 2020	4 Aug 2022
Application	Application METHOD FOR TREATING COMPLICATIONS RELATED TO ACUTE OR CHRONIC HYPERGLYCEMIA Filling date: 27 Sep 2018 Issue date: 17 Sep 2020	27 Sep 2018	17 Sep 2020

INmune Bio
Earnings Call Transcripts

Quarter	Transcript
Q1 2024 9 May 2024	Q1 2024 Earnings Call Transcript
Q4 2023 28 Mar 2024	Q4 2023 Earnings Call Transcript
Q3 2023 1 Nov 2023	Q3 2023 Earnings Call Transcript
Q2 2023 7 Aug 2023	Q2 2023 Earnings Call Transcript

INMB earnings call transcripts

INmune Bio
Executives

Insider	Age	Compensation
Mr. David J. Moss M.B.A. (1970) Chief Financial Officer, Treasurer & Sec.	55	$300,000
Dr. Raymond Joseph Tesi (1956) Co-Founder, Pres, Chief Executive Officer, Chief Medical Officer & Chairman	69	$300,000
Dr. Mark William Lowdell BSc, MSc, Ph.D., FRCPath, MICR (1963) Chief Scientific Officer & Chief Manufacturing Officer	62	$138,200

INmune Bio
Latest News

Wednesday, 4 December 2024
09:00	OmniScience Inc. and INmune Bio Inc. Partner to Accelerate a Phase 2 Alzheimer's Trial with Vivo, a Novel genAI Clinical Trial Control Tower	globenewswire.com
Thursday, 31 October 2024
20:09	INmune Bio, Inc. (INMB) Q3 2024 Earnings Call Transcript	seekingalpha.com
16:05	INmune Bio Inc. Announces Third Quarter 2024 Results and Provides Business Update	globenewswire.com
Monday, 28 October 2024
08:00	INmune Bio Inc. to Host Webinar on Cognitive Testing Using EMACC and CDR-SB	globenewswire.com
Thursday, 24 October 2024
15:03	INmune Bio Inc. Announces Publication in Cell Reports Demonstrating XPro™ Promotes Remyelination	globenewswire.com
09:30	INmune Bio Inc. to Report Third Quarter 2024 Financial Results and Provide Corporate Update on October 31, 2024	globenewswire.com
Friday, 11 October 2024
08:30	INmune Bio Inc. to Participate in the Maxim Healthcare Virtual Summit	globenewswire.com
Monday, 30 September 2024
05:04	INmune Bio: NK Cell Therapy INKmune For mCRPC Is Another Shot On Goal	seekingalpha.com
Thursday, 26 September 2024
08:00	INKmune™ Demonstrates Excellent Safety and Increased NK-Cell Activity in First Dosing Cohort	globenewswire.com
Tuesday, 17 September 2024
08:30	INmune Bio Announces Results of Additional Blinded Interim Analysis of Phase 2 Alzheimer's Disease Trial Demonstrating Correlation between EMACC and CDR-SB Endpoints	globenewswire.com
Friday, 13 September 2024
08:30	INmune Bio Announces $13.0 Million Registered Direct Offering	globenewswire.com
Tuesday, 3 September 2024
09:00	INmune Bio Inc. to Present at the Baird 2024 Global Healthcare Conference	globenewswire.com
Thursday, 1 August 2024
23:50	INmune Bio, Inc. (INMB) Q2 2024 Earnings Call Transcript	seekingalpha.com
16:05	INmune Bio Inc. Announces Second Quarter 2024 Results and Provides Business Update	globenewswire.com
Monday, 29 July 2024
09:00	INmune Bio Inc. Announces New Phase 1 Study Data Demonstrating Dose-Dependent Effect of XPro™ on Proteins that Regulation Synapses in Alzheimer's Patients	globenewswire.com
Thursday, 25 July 2024
08:00	INmune Bio Inc. to Report Second Quarter 2024 Financial Results and Provide a Corporate Update on Thursday, August 1, 2024	globenewswire.com
Tuesday, 23 July 2024
08:45	INmune Bio Inc. Publishes Novel Biology on Natural Killer Cancer Immunotherapy INKmune™ in the Journal for ImmunoTherapy of Cancer	globenewswire.com
Monday, 8 July 2024
06:12	INmune Bio: Promising Phase 2 Trials For Alzheimer's Drug XPro	seekingalpha.com
Friday, 5 July 2024
09:57	INmune Bio: Still A Bargain If Their Alzheimer's Program Reaches Its Inflection	seekingalpha.com
Thursday, 30 May 2024
08:00	INmune Bio Inc. to Join Russell 3000® Index	globenewswire.com
Saturday, 11 May 2024
20:58	INmune Bio, Inc. (INMB) Q1 2024 Earnings Call Transcript	Seeking Alpha
Monday, 22 April 2024
04:27	INmune Bio: An Opportunity In The Freefall (Rating Upgrade)	Seeking Alpha
Thursday, 28 March 2024
20:18	INmune Bio, Inc. (INMB) Q4 2023 Earnings Call Transcript	Seeking Alpha
Tuesday, 6 February 2024
09:00	INmune Bio to Participate in Baird's Biotech Discovery Series Webcast on February 13, 2024	GlobeNewsWire
Tuesday, 5 December 2023
03:58	Alzheimer's Disease Drug Development: Another Lost Year	Seeking Alpha
Sunday, 5 November 2023
20:28	7 Earnings Losers to Load Up On Right Now	InvestorPlace
Wednesday, 1 November 2023
22:38	INmune Bio, Inc. (INMB) Q3 2023 Earnings Call Transcript	Seeking Alpha
Monday, 31 July 2023
08:00	INmune Bio, Inc. to Report Second Quarter 2023 Financial Results and Provide a Corporate Update on Monday, August 7	GlobeNewsWire
Friday, 2 June 2023
14:26	INmune Bio's Alzheimer's treatment merits a high-upside price target, analysts say	Proactive Investors
Wednesday, 24 May 2023
09:00	INmune Bio Inc.'s Chief Scientific Officer, Mark Lowdell, Ph.D. to Present Plenary Talk at International Society of Cell & Gene Therapy	GlobeNewsWire

Frequently Asked Questions (FAQ)

What's the price of INmune Bio stock today?

One share of INmune Bio stock can currently be purchased for approximately $2.41.
When is INmune Bio's next earnings date?

Unfortunately, INmune Bio's (INMB) next earnings date is currently unknown.
Does INmune Bio pay dividends?

No, INmune Bio does not pay dividends.
How much money does INmune Bio make?

INmune Bio has a market capitalization of 98.88M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 58.56% to 155K US dollars.
What is INmune Bio's stock symbol?

INmune Bio, Inc. is traded on the NASDAQ under the ticker symbol "INMB".
What is INmune Bio's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of INmune Bio?

Shares of INmune Bio can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are INmune Bio's key executives?
INmune Bio's management team includes the following people:
- Mr. David J. Moss M.B.A. Chief Financial Officer, Treasurer & Sec.(age: 55, pay: $300,000)
- Dr. Raymond Joseph Tesi Co-Founder, Pres, Chief Executive Officer, Chief Medical Officer & Chairman(age: 69, pay: $300,000)
- Dr. Mark William Lowdell BSc, MSc, Ph.D., FRCPath, MICR Chief Scientific Officer & Chief Manufacturing Officer(age: 62, pay: $138,200)
Is INmune Bio founder-led company?

Yes, INmune Bio is a company led by its founder Dr. Raymond Joseph Tesi.
How many employees does INmune Bio have?

As Jul 2024, INmune Bio employs 11 workers, which is 10% more then previous quarter.
When INmune Bio went public?

INmune Bio, Inc. is publicly traded company for more then 6 years since IPO on 4 Feb 2019.
What is INmune Bio's official website?

The official website for INmune Bio is inmunebio.com.
Where are INmune Bio's headquarters?

INmune Bio is headquartered at 225 NE Mizner Boulevard, Boca Raton, FL.
How can i contact INmune Bio?

INmune Bio's mailing address is 225 NE Mizner Boulevard, Boca Raton, FL and company can be reached via phone at 858 964 3720.

INmune Bio, Inc.

inmunebio.com

Exchange:

NASDAQ

Full time employees:

Industry:

Biotechnology

Sector:

Healthcare

INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma and patients with high-risk myelodysplastic syndrome; INB03, an immunotherapy that treats patients with hematologic malignancies and solid tumors; and XPro1595 for the treatment of Alzheimer's disease. The company has license agreements with Xencor, Inc.; Immune Ventures, LLC; University of Pittsburg; and University College London. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.

858 964 3720

225 NE Mizner Boulevard
Boca Raton, FL 33432

CIK: 0001711754
ISIN: US45782T1051
CUSIP: 45782T105